Renalytix AI—developer of artificial intelligence ("AI") decision support and clinical management tools for improving early diagnosis, continual monitoring and drug development for kidney disease. incorporated in March 2018 as a subsidiary of EKF Diagnostics Holdings (AIM-EKF). Total fundraising in the range £21 - 25 m. Mkt cap - c. £67.5- £71.0m. Due 2 Nov.
Finncap—proposed acquisition of M&A adviser Cavendish Corporate Finance and AIM admission. Offer TBA
Kropz PLC—an emerging plant nutrie ....
26 Oct 2018
Small Cap Feast
Redx Pharma Plc (REDX:LON), 8.8 | Molecular Energies PLC (MEN:LON), 8.5 | Mincon Group Plc (MCON:LON), 45.0 | Hummingbird Resources plc (HUM:LON), 7.8 | Savannah Energy Plc (SAVE:LON), 26.4 | Sareum Holdings plc (SAR:LON), 27.5 | Itaconix plc (ITX:LON), 153 | Crawshaw Group (CRAW:LON), 0 | Brooks Macdonald Group plc (BRK:LON), 1,842 | Thalassa Holdings Ltd (THAL:LON), 24.5
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Small Cap Feast
Redx Pharma Plc (REDX:LON), 8.8 | Molecular Energies PLC (MEN:LON), 8.5 | Mincon Group Plc (MCON:LON), 45.0 | Hummingbird Resources plc (HUM:LON), 7.8 | Savannah Energy Plc (SAVE:LON), 26.4 | Sareum Holdings plc (SAR:LON), 27.5 | Itaconix plc (ITX:LON), 153 | Crawshaw Group (CRAW:LON), 0 | Brooks Macdonald Group plc (BRK:LON), 1,842 | Thalassa Holdings Ltd (THAL:LON), 24.5
- Published:
26 Oct 2018 -
Author:
Derren Nathan - Pages:
Renalytix AI—developer of artificial intelligence ("AI") decision support and clinical management tools for improving early diagnosis, continual monitoring and drug development for kidney disease. incorporated in March 2018 as a subsidiary of EKF Diagnostics Holdings (AIM-EKF). Total fundraising in the range £21 - 25 m. Mkt cap - c. £67.5- £71.0m. Due 2 Nov.
Finncap—proposed acquisition of M&A adviser Cavendish Corporate Finance and AIM admission. Offer TBA
Kropz PLC—an emerging plant nutrie ....